Figure 3.

NSG-UC mice benefit from treatment with DES1, infiximab, and tofacitinib. NSG mice were reconstituted with PBMCs from UC donors [n = 6] and were left unchallenged [Control, n = 12], or challenged with 10% ethanol at Day 8, 50% ethanol at Day 15, and treated on Days 7–9 and 14–17 with PBS [PBS, n = 37], 5 mg/kg DES1 [DES1, n = 36], or 5 mg/kg tofacitinib [tofacitinib [n = 12]. Infliximab was administered on Days 7 and 14 at a concentration of 6 mg/kg in PBS. [A] Clinical, colon, and histological scores depicted as Cumming plots. The upper part of the plot presents each data point in a swarm plot. In the lower panel of the plots, the effect sizes are shown. The 0 point of the difference axis indicates the mean of the reference group [PBS]. The dots show the difference between groups [effect size]. The shaded curve shows the entire distribution of excepted sampling error for the difference between the means. The error bar in the filled circles indicates the 95% confidence interval [bootstrapped] for the difference between means. [B] Representative macrophotographs of NSG-UC mice. Bar corresponds to 10 cm. [C] Representative microphotographs of haematoxylin-stained colonic sections from NSG-UC mice. Arrows indicate oedema and influx of inflammatory cells, bold arrows indicate goblet cell loss and fibrosis. [D] IHC of CD4+ T cells expressing Kv1.3 in a histological section of a PBS-treated mouse. Arrow indicates CD4+ positive cells, bold arrows double-positive CD4+ Kv1.3+ cells. PBMC, peripheral blood mononuclear cells; UC,ulcerative colitis; IHC, immunohistochemistry.